Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT)
$2.1500
+0.0900 ( +5.39% ) 4.7K
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Market Data
Open
$2.1500
Previous close
$2.0600
Volume
4.7K
Market cap
$4.84M
Day range
$1.9920 - $2.1890
52 week range
$1.3100 - $4.4000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Jun 14, 2024 |
8-k | 8K-related | 15 | Jun 14, 2024 |
8-k | 8K-related | 16 | Jun 05, 2024 |
8-k | 8K-related | 14 | May 29, 2024 |
8-k | 8K-related | 15 | May 20, 2024 |
8-k | 8K-related | 16 | May 09, 2024 |
10-q | Quarterly Reports | 58 | May 09, 2024 |
8-k | 8K-related | 15 | Mar 28, 2024 |
8-k | 8K-related | 16 | Mar 22, 2024 |
10-k | Annual reports | 70 | Mar 19, 2024 |